• Users Online: 132
  • Home
  • Print this page
  • Email this page

   Table of Contents      
Year : 2019  |  Volume : 67  |  Issue : 6  |  Page : 772-783

Coats disease in 351 eyes: Analysis of features and outcomes over 45 years (by decade) at a single center

1 Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, 840 Walnut Street, 14th Floor, Philadelphia, PA, USA
2 Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, 840 Walnut Street, 14th Floor, Philadelphia, PA; Department of Ophthalmology, Mayo Clinic, Rochester, MN, 55905, USA

Date of Submission05-Mar-2019
Date of Acceptance24-Apr-2019
Date of Web Publication24-May-2019

Correspondence Address:
Dr. Carol L Shields
Ocular Oncology Service, 840 Walnut Street, Suite 1440, Philadelphia, PA 19107
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijo.IJO_449_19

Rights and Permissions

Purpose: To assess features and outcomes of Coats disease over 5-decades. Methods: Retrospective review of Coats disease patients at a single center. Features and outcomes were compared based on decade of presentation. Results: There were 351 patients with Coats disease. The presenting median age (6 years), male sex (84%), and unilaterality (100%) did not change per decade. Coats disease classification did not change per decade with Stage 1 (1%), Stage 2 (21%), Stage 3 (68%), Stage 4 (6%), and Stage 5 (1%). Clinical features that changed per decade (1970s vs. 1980s vs. 1990s vs. 2000s vs. 2010s) included 1980s features of more eyes with exudation in all 4 quadrants (22% vs. 58% vs. 44% vs. 33% vs. 27, P = 0.01) and total exudative retinal detachment (33% vs. 53% vs. 39% vs. 27% vs. 21%, P < 0.001). Imaging features that changed per decade included 2010s greater fluorescein angiographic extent of retinal non-perfusion in mean clock hours (4 vs. 4 vs. 3 vs. 5 vs. 6, P = 0.003), and 1980s greater mean height of retinal detachment ultrasonographically (5 vs. 12 vs. 5 vs. 5 vs. 4 mm, P < 0.001). Treatment features that changed per decade included 1980s greater primary enucleation (11% vs. 16% vs. 3% vs. 4% vs. 1%, P = 0.001), and 2010s greater use of laser photocoagulation (55% vs. 33% vs. 38% vs. 40% vs. 72%, P < 0.001), sub-Tenon corticosteroid (0% vs. 4% vs. 5% vs. 8% vs. 29%, P < 0.001), and intravitreal anti-VEGF) (0% vs. 4% vs. 2% vs. 13% vs. 18%, P = 0.003). Outcomes that changed per decade included 2010s findings of more complete resolution of subretinal fluid (64% vs. 59% vs. 38% vs. 58% vs. 72%, P = 0.01) and less need for primary/secondary enucleation (17% vs. 27% vs. 14% vs. 13% vs. 6%, P = 0.04). Conclusion: Eyes with Coats disease in the 1980s demonstrated more advanced findings, often requiring enucleation. Over the decades, greater use of laser photocoagulation and injections has led to improved disease resolution with greater globe salvage.

Keywords: Coats disease, cryotherapy, enucleation, exudation, eye, laser photocoagulation, retina, surgery, telangiectasia

How to cite this article:
Shields CL, Udyaver S, Dalvin LA, Lim LS, Atalay HT, L Khoo CT, Mazloumi M, Shields JA. Coats disease in 351 eyes: Analysis of features and outcomes over 45 years (by decade) at a single center. Indian J Ophthalmol 2019;67:772-83

How to cite this URL:
Shields CL, Udyaver S, Dalvin LA, Lim LS, Atalay HT, L Khoo CT, Mazloumi M, Shields JA. Coats disease in 351 eyes: Analysis of features and outcomes over 45 years (by decade) at a single center. Indian J Ophthalmol [serial online] 2019 [cited 2023 Jan 29];67:772-83. Available from: https://www.ijo.in/text.asp?2019/67/6/772/259043

Support provided in part by the Eye Tumor Research Foundation, Philadelphia, PA (CLS). The funders had no role in the design and conduct of the study, in the collection, analysis and interpretation of the data, and in the preparation, review or approval of the manuscript. Carol L. Shields, M.D. has had full access to all the data in the study and takes responsibility for the integrity of the data.

Coats disease is a retinal vasculopathy characterized by retinal telangiectasia, micro- and macro- retinal aneurysms, intra- and subretinal exudation, and exudative retinal detachment. This condition typically manifests in children, but can occasionally be found in adults, and in both situations, this vasculopathy can threaten visual acuity. In 2001, a classification for Coats disease was established, based on clinical features in 150 consecutive cases at a single center and with the goal of establishing guidelines for treatment and prediction of globe salvage and visual acuity outcomes.[1],[2] This Coats disease classification included Stage 1 (retinal telangiectasia), Stage 2 (additional retinal exudation), Stage 3 (additional subretinal fluid), Stage 4 (additional total retinal detachment with neovascular glaucoma), and Stage 5 (endstage pre-phthisis bulbi or phthisis bulbi).[1] Further subdivision of stages 2 and 3 was provided to better assess extent and location of exudation and subretinal fluid. Since then, there have been several cohorts from India, Saudi Arabia, Turkey, Switzerland, United States, and other international centers analyzed based on this classification.[3],[4],[5],[6],[7],[8]

In recent years, we have noted more sophisticated treatment of Coats disease with vitreoretinal or subretinal/external drainage surgery, laser photocoagulation, and periocular and/or intravitreal medications leading to a reduction in the need for enucleation, especially in advanced-stage Coats disease.[9],[10],[11],[12],[13],[14],[15],[16],[17],[18] Herein, we provide a comprehensive overview of our 45-year experience with Coats disease diagnosis and management. We compare, by decade, the clinical and imaging features, management, and outcomes in 351 consecutive cases based on Coats disease classification.

  Methods Top

The medical, photographic, and imaging records of all patients diagnosed with Coats disease on the Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA from November 1, 1973 to July 31, 2018 were retrospectively reviewed. Patients with uncertain or alternative diagnoses were excluded. The records were then categorized based on decade at the time of presentation including 1973-1979 (1970s), 1980-1989 (1980s), 1990-1999 (1990s), 2000-2009 (2000s), 2010-2018 (2010s). The patient demographics, clinical features, imaging features, treatment modalities, and outcomes were then compared per decade.

Demographic data included age at presentation, race, sex, disease laterality, and study eye. Clinical features included presenting visual acuity (verbal or pre-verbal acuity), intraocular pressure (IOP) in mm Hg, Coats disease stage, presence, location, and extent of telangiectasia, aneurysms (light bulb), exudation, and subretinal fluid. Secondary anterior segment features included presence of xanthocoria, strabismus, corneal edema, anterior chamber cholesterolosis, iris neovascularization, iris atrophy, cataract, and phthisis bulbi.

Coats disease staging was based on a previously published classification as Stage 1 (only retinal telangiectasias), Stage 2A, (telangiectasia and extrafoveal exudation), Stage 2B (telangiectasia and foveal exudation), Stage 3A1 (subtotal extrafoveal exudative retinal detachment), Stage 3A2 (subtotal exudative retinal detachment involving the fovea), Stage 3B (total exudative retinal detachment), Stage 4 (total exudative retinal detachment and secondary glaucoma), or Stage 5 (advanced end-stage disease, phthisis bulbi).[1],[19] Previously-treated patients who were referred with partially or completely resolved disease were characterized as unknown for staging.

Imaging features included fluorescein angiography documentation of location and extent of telangiectasia, light bulb aneurysms, retinal non-perfusion, cystoid macular edema, and neovascularization of optic disc, retina, and iris; optical coherence tomography (OCT), documentation of cystoid macular edema, epiretinal membrane, vitreomacular traction, subretinal/intraretinal fluid or exudation, central macular thickness and subfoveal choroidal thickness; ultrasonography documentation of presence and extent of retinal detachment, retinal elevation (mm height), and subretinal exudation. Treatment features included use of observation, laser photocoagulation, cryotherapy, sub-Tenon's or intravitreal corticosteroid, intravitreal anti-vascular endothelial growth factor (anti-VEGF), or enucleation. The number of non-enucleation therapies were counted.

Outcomes included visual acuity, amblyopia patching, and resolution of disease in general and specifically with regard to telangiectasia, exudation, and subretinal fluid. Further outcomes included development of iris neovascularization, glaucoma, traction retinal detachment and need for pars plana vitrectomy or enucleation and time to enucleation.

Data were tabulated in Microsoft Excel 2016 and analyzed using SPSS software (version 18 for Windows; SPSS Inc., Chicago, IL, USA). Continuous variables are expressed as mean (median, range). Comparison of eyes of each decade was performed using Student sample t-test for continuous variables and Chi-square or Fisher's exact test for categorical variables. The mean time to enucleation was calculated per each decade.

  Results Top

There were 351 eyes of 351 patients with Coats disease in this analysis. Based on decade of presentation, number of patients per decade included 1970s (n = 18, 5%), 1980s (n = 43, 12%) 1990s (n = 66, 18%) 2000s (n = 112, 32%), and 2010s (2010-2018) (n = 112, 32%).

The demographic features are listed in [Table 1]. Overall median age at presentation was 6 years, race was Caucasian (72%), sex was male (84%), involvement was unilateral (100%), and left eye was affected (54%). A comparison of demographic features over the decades (1970s vs. 1980s vs. 1990s vs. 2000s vs. 2010s) revealed no significant difference in presenting age, race, sex, laterality, or affected eye (p > 0.05).
Table 1: Coats disease by decade in 351 eyes of 351 patients. Demographic characteristics

Click here to view

The clinical features are listed in [Table 2]. A comparison of features by decade revealed a difference in pre-verbal visual acuity, with greater no fix and follow vision in the 1980s and less in the 2010s (17% vs. 33% vs. 26% vs. 22% vs. 10%, P = 0.01). There were several clinical features that predominated in the 1980s including greater mean intraocular pressure (16 vs. 21 vs. 16 vs. 16 vs. 16 mmHg, P = 0.001), greater mean clock hours of exudation (7 vs. 9 vs. 8 vs. 7 vs. 6, P = 0.01), and greater prevalence of 4 quadrants of exudation (22% vs. 58% vs. 44% vs. 33% vs. 27, P = 0.01), 4 quadrants of subretinal fluid (29% vs. 56% vs. 42% vs. 38% vs. 35%, P = 0.02), and total exudative retinal detachment (33% vs. 53% vs. 39% vs. 27% vs. 21%, P < 0.001). Per decade, there was no difference in verbal visual acuity, Coats disease stage (complete and simplified), telangiectasia (clock hours, quadrant, and location), light bulb aneurysms (clock hours, quadrant, and location), and other posterior and anterior segment findings of neovascularization of the optic disc, retina and iris.
Table 2: Coats disease by decade in 351 eyes of 351 patients. Clinical characteristics

Click here to view

The imaging features are listed in [Table 3]. A comparison of imaging features by decade revealed the 2010s with greater mean clock hours of peripheral non-perfusion (4 vs. 4 vs. 3 vs. 5 vs. 6, P = 0.003). There were several imaging features that predominated in the 1980s including greater presence of retinal detachment by ultrasonography (60% vs. 83% vs. 82% vs. 59% vs. 48%, P = 0.01), greater mean elevation of subretinal fluid by ultrasonography (5 vs. 12 vs. 5 vs. 5 vs. 4 mm, P < 0.001), and more prevalent closed funnel retinal detachment (0% vs. 33% vs. 7% vs. 7% vs. 9%, P = 0.01). Per decade, there was no difference in fluorescein angiographic documentation of telangiectasia (extent, location, and quadrant), light bulb aneurysm (extent, location, and quadrant), cystoid macular edema, and neovascularization of the optic disc, retina, and iris.
Table 3: Coats disease by decade in 351 eyes of 351 patients. Imaging features

Click here to view

The treatment features are listed in [Table 4]. A comparison of treatment features by decade revealed several features in the 2010s with less frequent management with observation (39% vs. 21% vs. 33% vs. 21% vs. 11%, P = 0.002), greater total number of treatments (2.9 vs. 2.0 vs. 1.8 vs. 3.6 vs. 4.5, P = 0.001), and more use of argon laser photocoagulation (55% vs. 33% vs. 38% vs. 40% vs. 72%, P < 0.001), sub-Tenon corticosteroid injection (0% vs. 4% vs. 5% vs. 8% vs. 29%, P < 0.001), and intravitreal anti-VEGF (0% vs. 4% vs. 2% vs. 13% vs. 18%, P = 0.003). Fewer eyes in the 2010s were treated with primary enucleation (11% vs. 16% vs. 3% vs. 4% vs. 1%, P = 0.001). Per decade, there was no difference in cryotherapy use.
Table 4: Coats disease by decade in 351 eyes of 351 patients. Treatment features

Click here to view

The outcomes are listed in [Table 5]. A comparison of outcomes by decade revealed longer follow-up for patients who presented in the 1970s (118 vs. 101 vs. 66 vs. 54 vs. 32 months, P < 0.001). Eyes from the 2010s had more complete disease resolution (58% vs. 45% vs. 37% vs. 55% vs. 73%, P = 0.002), more complete subretinal fluid resolution (64% vs. 59% vs. 38% vs. 58% vs. 72%, P = 0.01), and fewer overall need for primary or secondary enucleation (17% vs. 27% vs. 14% vs. 13% vs. 6%, P = 0.04). On sub-analysis with Fisher's exact test, disease resolution was more likely in eyes from the 2010s compared to eyes in the 1980s (p = 0.01) and 1990s (p = 0.002); subretinal fluid resolution was more likely in eyes from the 2010s compared to eyes in the 1990s (p < 0.001); andenucleation was less likely in patients seen in the 2010s compared to patients seen in the 1980s (p = 0.003). Per decade, there was no difference in development of iris neovascularization, traction retinal detachment, glaucoma, and need for pars plana vitrectomy.
Table 5: Coats disease by decade in 351 eyes of 351 patients. Outcomes

Click here to view

  Discussion Top

Coats disease represents a broad clinical spectrum of retinal vasculopathy, predominantly in children, and demonstrating telangiectasia, exudation, retinal detachment, and occasionally neovascular glaucoma or phthisis bulbi.[1],[2],[3],[4],[5],[6],[7],[8],[9],[10],[11],[12],[13],[14],[15],[16],[17],[18] The management of Coats disease begins with documentation of the extent of vasculopathy using clinical examination and imaging, particularly with fluorescein angiography. When extensive exudation or retinal detachment is present, Coats disease can simulate malignant retinoblastoma. In a comprehensive analysis of 2781 patients referred with possible retinoblastoma, 604 (22%) had pseudoretinoblastoma, with the leading three conditions including Coats disease (n = 244, 40%), persistent fetal vasculature (PFV) (n = 158, 28%), and vitreous hemorrhage (n = 27, 5%), comprising 73% of the simulators.[20] In that analysis, based on age, pseudoretinoblastoma under the age of 1 year was most likely PFV (49%), whereas it was more likely Coats disease for those age 2-5 years (61%) and those older than 5 years (57%).[20] These simulating conditions can be sorted to the correct diagnosis with the recognition of classic clinical and imaging features like exudative retinal detachment, irregularly-dilated telangiectactic retinal vessels, and peripheral non-perfusion of Coats disease compared to serous retinal detachment, solid tumor with seeding, and tortuous, but smoothly-dilated retinal vessels of retinoblastoma.[9],[19],[21]

In this analysis, we reviewed our 45-year experience with Coats disease, decade-by-decade. We found that several factors have not changed over the years such as median patient age at 6 years, predominant race as Caucasian (72%), and sex as male (84%). Importantly, there was no difference in Coats disease stage (complete or simplified) over this period. However, there were a few features that changed over time, with significantly more advanced Coats disease in the 1980s, demonstrating higher intraocular pressure (p = 0.001), greater degree of exudation (p = 0.01) and subretinal fluid (p = 0.02), and more frequent total exudative retinal detachment (p < 0.001), all likely related to poorer entering verbal visual acuity (<20/200 (35%) P = 0.10) and preverbal visual acuity (no fix or follow (33%) P = 0.01). In fact, in the 1980s, exudative retinal detachment was significantly more highly elevated ultrasonographically (p < 0.001), a feature that has been subsequently correlated with need for enucleation.[22] Udyaver et al. studied features of Coats disease predictive of enucleation and found that each 1 millimeter increase in exudative retinal detachment thickness (by ultrasonography) increased the risk for enucleation by 20% (odds ration [OR] = 1.20) and each additional clock hour of light bulb aneurysms increased the risk by 35% (OR = 1.35).[22] Khoo et al. studied factors predictive of exudative retinal detachment resolution following treatment of eyes with Coats disease and noted that every 1 mm decrease in exudative retinal detachment elevation was associated with improved fluid resolution by 16%.[23]

Coats disease is typically discovered in the pediatric age group. In this analysis, the median age at presentation was 6 years and the mean age was 12 years (with range up to 79 years), maintained at a fairly steady level throughout the 5 decades. In 2001, a report from the United States (US) on 150 cases of Coats disease found median age at 5 years, mean age at 11 years with range up to 63 years, male prevalence at 76%, and unilaterality at 95%.[1],[2] Later, in 2010, a population-based study from the United Kingdom (UK) on 55 cases revealed median age at 8 years and mean age at 12 years, again skewed by a small number of cases presenting in later adult life.[24] In the UK study, all cases were unilateral and 85% were male, as in our report. The estimated population-based incidence was 0.09/100,000 persons and they noted 44% of patients were blind (20/200 or worse) at diagnosis and younger patients demonstrated more severe stages of Coats disease.[24] They concluded that Coats disease in young patients have increased disease severity with poorer visual acuity.[24] Daruich et al. studied age of onset of Coats disease in 98 cases from Switzerland in which mean age at diagnosis was 5 years and they found that younger age at presentation was associated with more advanced stage and worse visual prognosis.[7] There were several features that were more severe in young patients such as the presence of leukocoria, strabismus, areas of peripheral non-perfusion and telangiectasia, and foveal compromise with poor visual acuity and ultimate need for enucleation.[7] In our department, Dalvin et al. studied age of onset of Coats disease in 351 cases, the largest-yet studied cohort, and concurred that younger age (≤3 years at diagnosis) typically manifested more advanced Coats disease stage, worse visual acuity, and more likely to require enucleation.[25]

In this analysis of Coats disease, we tabulated treatment strategies by decade of presentation and found important changes over the years, as in the 2010s there was greater use of laser photocoagulation (55% vs. 33% vs. 38% vs. 40% vs. 72%, P < 0.001), sub-Tenon corticosteroid (0% vs. 4% vs. 5% vs. 8% vs. 29%, P < 0.001), and intravitreal anti-vascular endothelial growth factor (VEGF) (0% vs. 4% vs. 2% vs. 13% vs. 18%, P = 0.003), that could have partially lead to less need for enucleation (17% vs. 27% vs. 14% vs. 13% vs. 6%, P = 0.04). The use of laser photocoagulation in the past was limited to eyes with nearly flat retina as it was believed that laser to highly detached retina could lead to development of retinal hole and rhegmatogenous detachment. However, several authors have demonstrated that this is not the case and laser treatment can be employed for total retinal detachment, as is often seen in the youngest children.[14],[25],[26]

There have been few longitudinal studies on Coats disease. Ong et al. reviewed 39 cases of Coats disease based on two decades (decade 1 (1995-2005) versus decade 2 (2006-2015).[8] They noted that patients in decade 1 demonstrated more advanced disease and with worse final visual acuity, whereas those from decade 2 were less often managed with observation and had more procedures per eye. In our series over 5 decades, we similarly observed the most advanced disease in the 1980s and gradual shift toward greater treatments with laser photocoagulation, injections of corticosteroid and anti-VEGF with greater resolution of subretinal fluid and fewer cases of enucleation.

There are limitations to this retrospective analysis extending over 5 decades. First, diagnostic accuracy and treatment strategy have improved over time and misdiagnosis as a simulating lesion with eventual diagnostic enucleation is rarely performed nowadays. Further, current improvements in retinal imaging with hand-held portable camera with wide angle fluorescein angiography, ipad tablet ultrasonography, and hand-held optical coherence tomography all add ease and specificity for diagnostic imaging. Most of these imaging modalities were not available or were in rudimentary development during the 1970s and 1980s and were improved in the 1990s. Additionally, improved methods for treatment of total retinal detachment from early macroscopic retinal detachment surgery to current microscopic methods of external drainage, vitrectomy, and periocular or intraocular medication injections have evolved over time. Lasers have improved during this period from relatively immobile xenon arc photocoagulator to more portable argon and diode laser photocoagulation. These factors could have impacted outcomes in this series.

  Conclusion Top

In summary, we have carefully surveyed a single center experience with Coats disease over 5 decades and found no difference in age race, sex, or Coats disease stage at presentation, but did note more advanced exudative retinopathy in the 1980s with need for enucleation, while in the 2010s greater use of laser photocoagulation, injection of medications, and ultimate globe salvage was documented.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Shields JA, Shields CL, Honavar SG, Demirci H, Cater J. Classification and management of coats disease: The 2000 proctor lecture. Am J Ophthalmol 2001;131:572-83.  Back to cited text no. 1
Shields JA, Shields CL, Honavar SG, Demirci H. Clinical variations and complications of coats disease in 150 cases: The 2000 Sanford Gifford memorial lecture. Am J Ophthalmol 2001;131:561-71.  Back to cited text no. 2
Rishi P, Rishi E, Uparkar M, Sharma T, Gopal L, Bhende P, et al. Coats' disease: An Indian perspective. Indian J Ophthalmol 2010;58:119-24.  Back to cited text no. 3
[PUBMED]  [Full text]  
Al-Qahtani AA, Almasaud JM, Ghazi NG. Clinical characteristics and treatment outcomes of coats disease in a Saudi Arabian population. Retina 2015;35:2091-9.  Back to cited text no. 4
Cebeci Z, Bayraktar S, Yilmaz YC, Tuncer S, Kır N. Evaluation of follow-up and treatment results in Coats' disease. Turk J Ophthalmol 2016;46:226-31.  Back to cited text no. 5
Daruich AL, Moulin AP, Tran HV, Matet A, Munier FL. Subfoveal nodule in coats disease: Toward an updated classification predicting visual prognosis. Retina 2017;37:1591-8.  Back to cited text no. 6
Daruich A, Matet A, Munier FL. Younger age at presentation in children with Coats disease is associated with more advanced stage and worse visual prognosis: A retirospective study. Retina 2018;38:2239-46.  Back to cited text no. 7
Ong SS, Buckley EG, McCuen BW 2nd, Jaffe GJ, Postel EA, Mahmoud TH, et al. Comparison of visual outcomes in Coats' disease: A 20-year experience. Ophthalmology 2017;124:1368-76.  Back to cited text no. 8
Sigler EJ, Randolph JC, Calzada JI, Wilson MW, Haik BG. Current management of coats disease. Surv Ophthalmol 2014;59:30-46.  Back to cited text no. 9
Silodor SW, Augsburger JJ, Shields JA, Tasman W. Natural history and management of advanced Coats' disease. Ophthalmic Surg 1988;19:89-93.  Back to cited text no. 10
Li AS, Capone A Jr, Trese MT, Sears JE, Kychenthal A, De la Huerta I, et al. Long-term outcomes of total exudative retinal detachments in stage 3B coats disease. Ophthalmology 2018;125:887-93.  Back to cited text no. 11
Desai SR, Sayem OA, Chakravarti A, Natarajan S. Modified transscleral external drainage of subretinal fluid in high bullous exudative retinal detachment due to Coats' disease. Oman J Ophthalmol 2018;11:181-3.  Back to cited text no. 12
[PUBMED]  [Full text]  
Rao P, Knapp AN, Todorich, Drenser KA, Trese MT, Capone A Jr. Anatomical surgical outcomes of patients with advanced coats disease and coats-like detachments: Review of literature. Novel surgical technique, and subset analysis in patients with facioscapulohumeral muscular dystrophy. Retina 2019; Feb 14. doi: 10.1097/IAE.0000000000002463. [Epub ahead of print]  Back to cited text no. 13
Levinson JD, Hubbard GB. 577-nm yellow laser photocoagulation for Coats disease. Retina 2016;36:1388-94.  Back to cited text no. 14
Ramasubramanian A, Shields CL. Bevacizumab for coats' disease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol 2012;96:356-9.  Back to cited text no. 15
Gaillard MC, Mataftsi A, Balmer A, Houghton S, Munier FL. Ranibizumab in the management of advanced coats disease stages 3B and 4: Long-term outcomes. Retina 2014;34:2275-81.  Back to cited text no. 16
Zhang L, Ke Y, Wang W, Shi X, Hei K, Li X. The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for coats' disease. Graefes Arch Clin Exp Ophthalmol 2018;256:1339-46.  Back to cited text no. 17
Belin PJ, Lee AC, Greaves G, Kosoy J, Lieberman RM. The use of bevacizumab in pediatric retinal and choroidal disease: A review. Eur J Ophthalmol 2019; Feb 13:1120672119827773. doi: 10.1177/1120672119827773. [Epub ahead of print].  Back to cited text no. 18
Shields JA, Shields CL. Review: Coats disease: The 2001 LuEsther T. Mertz lecture. Retina 2002;22:80-91.  Back to cited text no. 19
Shields CL, Schoenfeld E, Kocher K, Shukla SY, Kaliki S, Shields JA. Lesions simulating retinoblastoma (pseudoretinoblastoma) in 604 cases. Ophthalmology 2013;120:311-6.  Back to cited text no. 20
Shields JA, Shields CL. Differentiation of Coats' disease and retinoblastoma. J Ped Ophthalmol Strabism 2001;38:262-6.  Back to cited text no. 21
Udyaver S, Dalvin LA, Lim LAS, Mazloumi M, Atalay HT, Khoo CTL, et al. Predictors of enucleation in Coats disease: Analysis of 259 eyes at a single center. J AAPOS 2019;[In Press].  Back to cited text no. 22
Khoo CTL, Dalvin LA, Lim LS, Udyaver S, Atalay HT, Mazloumi M, et al. Factors predictive of subretinal fluid resolution in Coats disease: Analysis of 177 eyes in 177 patients at a single center. Asia Pac J Ophthalmol 2019; [In Press].  Back to cited text no. 23
Morris B, Foot B, Mulvihill A. A population-based study of coats disease in the United Kingdom I: Epidemiology and clinical features at diagnosis. Eye 2010;24:1797-801.  Back to cited text no. 24
Dalvin LA, Udyaver S, Lim LS, Mazloumi M, Atalay HT, Khoo CTL, et al. Coats disease: Clinical features and outcomes by age category in 351 cases. J Pediatr Ophthalmol Strabism 2019; [In Press].  Back to cited text no. 25
Schefler AC, Berrocal AM, Murray TG. Advanced Coats' disease. Management with repetitive aggressive laser ablation therapy. Retina 2008;28:S38-41.  Back to cited text no. 26


  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5]

This article has been cited by
1 Coats plus syndrome with new observation of drusenoid retinal pigment epithelial detachments in a teenager
Kushal U. Agrawal, Nicholas E. Kalafatis, Carol L. Shields
American Journal of Ophthalmology Case Reports. 2022; 28: 101713
[Pubmed] | [DOI]
Philip J. DeSouza, Craig M. Greven
RETINAL Cases & Brief Reports. 2022; 16(2): 149
[Pubmed] | [DOI]
Constantinos D. Georgakopoulos, Foteini N. Tsapardoni, Olga E. Makri, Demetrios Vavvas
RETINAL Cases & Brief Reports. 2022; 16(4): 473
[Pubmed] | [DOI]
4 Plentiful melanin pigment containing histiocyte-like cells in Coats disease: Awareness avoids diagnostic pitfall
Malvika Shastri, Reetu Kundu, Simar Rajan Singh, Vishali Gupta, Vipin Rana
Cytopathology. 2022;
[Pubmed] | [DOI]
5 Coats disease in India: clinical presentation and outcome in 675 patients (690 Eyes)
Phuntsho Dorji, Vishal Raval, Subhadra Jalali, Niroj Sahoo, Tapas Ranjan Padhi, Swathi Kaliki, Anthony Vipin Das
International Ophthalmology. 2022;
[Pubmed] | [DOI]
6 Clinicopathological Correlations in Enucleated Globes of Late-Stage Coats Disease with a Review of the Literature
Hala A. Helmi, Abdullah Jammah, Azza MY. Maktabi, Saleh AlMesfer, Hind M. Alkatan
Journal of Epidemiology and Global Health. 2022;
[Pubmed] | [DOI]
7 Phenotype of Coats disease in females
Alejandra Daruich, Francis L Munier
BMJ Open Ophthalmology. 2022; 7(1): e000883
[Pubmed] | [DOI]
8 Genetic evaluation in phenotypically discordant monozygotic twins with Coats Disease
Rosario Alfio Umberto Lizzio, Edoardo Monfrini, Simona Romano, Gloria Brescia, Stela Vujosevic, Matteo Sacchi, Alessio Di Fonzo, Paolo Nucci
European Journal of Ophthalmology. 2022; : 1120672122
[Pubmed] | [DOI]
9 Coats disease in adolescence and adulthood with preserved vision after laser photocoagulation monotherapy: two case reports
Gitalisa Andayani Adriono, Andi Marsa Nadhira, Sausan Rasyid Mahfudz
Journal of Medical Case Reports. 2022; 16(1)
[Pubmed] | [DOI]
10 Imaging methods in the differential diagnosis of retinoblastoma, Coats’ disease and primary persistent hyperplastic vitreous
Yu. V. Artemenko, T. R. Panferova, E. V. Mikhailova, Yu. Kyun, T. L. Ushakova, V. G. Polyakov
Russian Journal of Pediatric Hematology and Oncology. 2022; 9(1): 11
[Pubmed] | [DOI]
11 Effectiveness of laser coagulation in children with Coats’ disease
Elena N. Demchenko, Ekaterina V. Denisova, Ludmila V. Kogoleva, Marya V. Belova, Natalya A. Osipova
Russian Pediatric Ophthalmology. 2022; 17(3): 5
[Pubmed] | [DOI]
12 Experience with Intravitreal Ranibizumab as an Adjunct to Ablation Therapy in Eyes with Exudative Coats’ Disease
Mohamed Nowara, Yousef A Fouad, Ihab Abdel Aziz, Ahmed M Habib, Mariam Al-feky, Hisham Hassan
Clinical Ophthalmology. 2021; Volume 15: 367
[Pubmed] | [DOI]
13 Advanced Coats' disease: Cytopathology to the rescue!
Deeksha Katoch, Sabia Handa, Rashmi Joshi, Usha Singh, Manish Rohilla
Diagnostic Cytopathology. 2021; 49(11): 1217
[Pubmed] | [DOI]
14 Clinical Characteristics of Pediatric Coats' Disease With Retinal Cyst Using Wide-Angle Fluorescein Angiography
Jing-Hua Liu, Guangda Deng, Jing Ma, Liang Li, Yuxin Fang, Songfeng Li, Hai Lu
Frontiers in Medicine. 2021; 8
[Pubmed] | [DOI]
15 Idiopathic Peripheral Retinal Telangiectasia in Adults: A Case Series and Literature Review
Maciej Gawecki
Journal of Clinical Medicine. 2021; 10(8): 1767
[Pubmed] | [DOI]
16 Fovea-sparing coats disease: A rare clinical entity
Matteo Maria Girolamo, Sonia De Francesco, Federica Salvoldi, Matteo Barchitta, Cristina Menicacci, Theodora Hadjistilianou
European Journal of Ophthalmology. 2021; 31(6): 3405
[Pubmed] | [DOI]
17 The blood–retina barrier in health and disease
Fionn O’Leary, Matthew Campbell
The FEBS Journal. 2021;
[Pubmed] | [DOI]
18 Clinical features and prognostic factors in 71 eyes over 20 years from patients with Coats’ disease in Korea
Hyun Goo Kang, Jung Dong Kim, Eun Young Choi, Suk Ho Byeon, Sung Soo Kim, Hyoung Jun Koh, Min Kim
Scientific Reports. 2021; 11(1)
[Pubmed] | [DOI]
19 Vitrectomy and external drainage of subretinal fluid containing high concentration of vascular endothelial growth factor for advanced coats disease
Fukutaro Mano, Itsuka Matsushita, Hiroyuki Kondo, Shoko Utamura, Chiori Kondo, Shunji Kusaka
Scientific Reports. 2021; 11(1)
[Pubmed] | [DOI]
20 Coats Disease in 9 Patients: A Hispanic Case Series
Maximiliano Barrera-Sánchez, Rosa E. Martinez-Muñoz, Raul E. Ruiz-Lozano, Catharina Busch, Juan Homar Paez-Garza, Patricio J. Rodriguez-Valdes
Klinische Monatsblätter für Augenheilkunde. 2021;
[Pubmed] | [DOI]
21 Visual acuity outcomes in Coats disease by classification stage in 160 patients
Carol L Shields, Sanika Udyaver, Lauren A Dalvin, Li-Anne S Lim, Hatice T Atalay, Chloe Khoo, Mehdi Mazloumi, Jerry A Shields
British Journal of Ophthalmology. 2020; 104(3): 422
[Pubmed] | [DOI]
22 Advanced Coats’ disease treated with intravitreal brolucizumab combined with laser photocoagulation
Nimesh A. Patel, Audina M. Berrocal, Timothy G. Murray, Victor M. Villegas
American Journal of Ophthalmology Case Reports. 2020; 19: 100815
[Pubmed] | [DOI]
23 Three-year follow-up of Coats disease treated with conbercept and 532-nm laser photocoagulation
Li Jiang, Bo Qin, Xiao-Ling Luo, He Cao, Ting-Ming Deng, Ming-Ming Yang, Ting Meng, Hui-Qin Yang
World Journal of Clinical Cases. 2020; 8(24): 6243
[Pubmed] | [DOI]
24 Optical coherence tomography in pediatric patients: a clinical review
Bradley S. Gundlach, Irena Tsui
Therapeutic Advances in Ophthalmology. 2020; 12: 2515841420
[Pubmed] | [DOI]
25 Neglected Coats Disease
Megan Ruben, Antonio Yaghy, Carl H. Park, Carol L. Shields
Journal of Pediatric Ophthalmology & Strabismus. 2020; 57(6)
[Pubmed] | [DOI]
26 Coats Disease: Clinical Features and Outcomes by Age Category in 351 Cases
Lauren A. Dalvin, Sanika Udyaver, Li-Anne S. Lim, Mehdi Mazloumi, Hatice T. Atalay, Chloe T. L. Khoo, Carol L. Shields
Journal of Pediatric Ophthalmology & Strabismus. 2019; 56(5): 288
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
Article Tables

 Article Access Statistics
    PDF Downloaded429    
    Comments [Add]    
    Cited by others 26    

Recommend this journal